Obama's stem cell policy is welcome change, but ethics are permanent feature of debate
By Jesse Reynolds,
The Jurist online
| 03. 18. 2009
President Obama's recent removal of his predecessor's stem cell policy is a welcome development. The Bush administration's restriction on the federal funding of human embryonic stem cell research was outdated and increasingly unpopular. While much of the media coverage of President Obama's announcement has focused on the research's potential and the political winners and losers, here are a few points that were overlooked:
For years, embryonic stem cell research in the US has been conducted in a federal regulatory vacuum, and the debate has been characterized by exaggerated rhetoric about imminent cures. Obama shifted the ground on both fronts. He ordered the National Institutes of Health(NIH) to draw up guidelines, which hopefully will be enforceable and apply to both publicly and privately funded research. The President also clearly called for a prohibition on reproductive cloning, which remains legal in the US and shares materials and methods with embryonic stem cell research. Furthermore, his language was optimistic but cautious; he noted that cures may not come in our lifetimes. This is a big change from advocates' over-the-top promises...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...